Coffee Holding Co., Inc. JVA
We initially cited our interest in JVA at 8.35, and the stock ran as high as 14.40 for a 72 percent gain. On Friday, the stock closed at 11.30, still a gain of 35 percent from our originating call.
Moving forward, JVA will remain on our watchlist for its prime performance, and our expectation that there are more positives on the horizon.
Exit Only, Inc. EXTO
It has been quite some time since we mentioned EXTO, a stock that first popped onto our radar in July, thereupon making a massive move for us.
Last week, there was a large volume selloff, and we saw a retrace to the lowest price we have seen since July. Currently the RSI smacks of overselling, which is why we presumed to mention this play again, as a rebound from these conditions and prices seems highly plausible.
Stellar Resources, Ltd. SRRL
We have noticed that after a big sell-off, the stock is building support in the .02 range, and it is going to be interesting to see how the stock trends, as it begins to rebound off of its bottom.
Just 2-3 weeks back , the stock was trading in the five to six cent range, and we believe it could easily return to that level, which would yield gains of over 100-200 percent.
Mistral Ventures, Inc. MILV
We wanted to mention MILV again this morning, after some post-market news on Friday could really cause a stir, considering the nature of the company’s claims. If even a fraction of the estimated revenue from the following press release materializes for MILV, the results could be satifying for investors.
CAPE CORAL, Fla., Oct. 28, 2011 /PRNewswire via COMTEX/ — Nature’s Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. (MILV.pk) announced that it has come to an agreement for the purchase of the newly formulated Sinus-Restore Sinus Relief Formula. Nature’s has tendered a deposit against formal closing, which is expected within 3 weeks. At the request of the inventor, to protect his privacy, financial terms are not to be disclosed in press releases.
The Center for Disease Control and Prevention estimates that close to 31 million adults in the US suffer from chronic sinusitis, resulting in 12.5 million ambulatory care visits per year and more than 200,000 sinus surgical procedures every year. Acute sinusitis is even more common, though there are no good estimates for the number of people who experience an episode of acute sinusitis every year.
Robert deZanger, CEO of Nature’s Bioceuticals states, “We are excited about bringing this product to market. Approximately 13% of the adult population suffers from chronic sinusitis. Billions of dollars per year are wasted on doctor visits and antibiotics that are unnecessarily prescribed to treat viral infections for which they will not help. Our all natural product has been shown to provide relief in a few short days. We expect to finalize the purchase within the next 21 days and to have product manufactured and ready for sale approximately 21 days thereafter. The product should also have far reaching impact for the relief of nasal discomfort due to allergies and cold and flu. The product is inexpensive to produce and we believe it will command a substantial market share in the three different markets therefore producing substantial revenues for the company. We anticipate sales in excess of $10,000,000.00 the first year and then expanding exponentially thereafter.”
Incoming search terms:
- hot jva com
- hot jva
- hot-jva com